Biology Reference
In-Depth Information
129. Zhang Q, Faca V, Hanash S. Mining the plasma pro-
teome for disease applications across seven logs of
protein abundance.
J Proteome Res
2011;
143. Michalski A, Damoc E, Hauschild JP, et al. Mass
spectrometry-based proteomics using Q Exactive,
a high-performance benchtop quadrupole Orbitrap
mass spectrometer.
Mol Cell Proteomics
2011;
:46
e
50.
130. Surinova S, Schiess R, Huttenhain R, et al. On the
development of plasma protein biomarkers.
J Proteome
Res
2011;
10
:M111
10
011015.
144. Ramanathan R, Jemal M, Ramagiri S, et al. It is time
for a paradigm shift in drug discovery bioanalysis:
from SRM to HRMS.
J Mass Spectrom
2011;
:5
e
16.
131. Picotti P, Aebersold R. Selected reaction monitoring-
based proteomics: work
10
ows, potential, pitfalls and
future directions.
Nat Methods
2012;
:595
e
601.
145. Yoshihara HA, Mahrus S, Wells JA. Tags for labeling
protein N-termini with subtiligase for proteomics.
Bioorg Med Chem Lett
2008;
46
:555
e
66.
132. Boja ES, Rodriguez H. Mass spectrometry-based tar-
geted quantitative proteomics: achieving sensitive and
reproducible detection of proteins.
Proteomics
2012;
9
:6000
e
3.
146. Mahrus S, Trinidad JC, Barkan DT, et al. Global
sequencing of proteolytic cleavage sites in apoptosis
by speci
18
:
12
1093
e
110.
133. Yao X, Bajrami B, Shi Y. Ultrathroughput multiple
reaction monitoring mass spectrometry.
Anal Chem
2010;
c labeling of protein N termini.
Cell
2008;
:
134
866
e
76.
147. Wildes D, Wells JA. Sampling the N-terminal pro-
teome of human blood.
Proc Natl Acad Sci USA
2010;
107
:794
e
7.
134. Sherman J, McKay MJ, Ashman K, et al. How speci
82
c
is my SRM?: The issue of precursor and product ion
redundancy.
Proteomics
2009;
:4561
e
6.
148. Agard NJ, Maltby D, Wells JA. In
:1120
e
3.
135. Makawita S, Diamandis EP. The bottleneck in the
cancer biomarker pipeline and protein quanti
9
ammatory stimuli
regulate caspase substrate pro
les.
Mol Cell Proteomics
cation
through mass spectrometry-based approaches: current
strategies for candidate veri
:880
e
93.
149. Domon B. Glycosylation as means of reducing sample
complexity to enable quantitative proteomics.
Proteo-
mics
2009;
2010;
9
cation.
Clin Chem
2010;
:212
e
22.
136. Tang HY, Beer LA, Barnhart KT, et al. Rapid
veri
:1488
e
91.
150. Fortin T, Salvador A, Charrier JP, et al. Multiple
reaction monitoring cubed for protein quanti
56
9
cation at
cation of candidate serological biomarkers using
gel-based, label-free multiple reaction monitoring.
J Proteome Res
2011;
the low nanogram/milliliter level
in nondepleted
:4005
e
17.
137. Anderson NL, Anderson NG, Haines LR, et al. Mass
spectrometric quantitation of peptides and proteins
using Stable Isotope Standards and Capture by Anti-
Peptide Antibodies (SISCAPA).
J Proteome Res
2004;
:9343
e
52.
151. Fortin T, Salvador A, Charrier JP, et al. Clinical
quantitation of prostate-speci
human serum.
Anal Chem
2009;
10
81
c antigen biomarker in
the low nanogram/milliliter range by conventional
bore liquid chromatography-tandem mass spectrom-
etry (multiple reaction monitoring) coupling and
correlation with ELISA tests.
Mol Cell Proteomics
2009;
8
:
3
235
e
44.
138. Anderson L, Hunter CL. Quantitative mass spectro-
metric multiple reaction monitoring assays for major
plasma proteins.
Mol Cell Proteomics
2006;
:1006
e
15.
152. Anderson NL, Anderson NG, Pearson TW, et al. A
human proteome detection and quantitation project.
Mol Cell Proteomics
2009;
:573
e
88.
139. Whiteaker JR, Zhao L, Anderson L, et al. An auto-
mated and multiplexed method for high throughput
peptide immunoaf
5
:883
e
6.
153. Kitteringham NR, Jenkins RE, Lane CS, et al. Multiple
reaction monitoring for quantitative biomarker anal-
ysis in proteomics and metabolomics.
J Chromatogr B
Analyt Technol Biomed Life Sci
2009;
8
nity enrichment and multiple
reaction monitoring mass spectrometry-based quanti-
fication of protein biomarkers.
Mol Cell Proteomics
2010;
:184
e
96.
140. AhnYH, Lee JY, KimYS, et al. Quantitative analysis of an
aberrant glycoform of TIMP1 from colon cancer serum
by L-PHA-enrichment and SISCAPA with MRM mass
spectrometry.
JProteomeRes
2009;
9
:1229
e
39.
154. Duncan MW, Yergey AL, Patterson SD. Quantifying
proteins by mass spectrometry: the selectivity of SRM
is only part of the problem.
Proteomics
2009;
877
:1124
e
7.
155. MacLean B, Tomazela DM, Shulman N, et al. Skyline:
an open source document editor for creating and
analyzing targeted proteomics
9
:4216
e
24.
141. Kuhn E, Addona T, Keshishian H, et al. Developing
multiplexed assays for troponin I and interleukin-33 in
plasma by peptide immunoaf
8
experiments.
Bio-
nity enrichment and tar-
geted mass spectrometry.
Clin Chem
2009;
:966
e
8.
156. Abbatiello SE,Mani DR, KeshishianH, et al. Automated
detection of inaccurate and imprecise transitions in
peptide quanti
informatics
2010;
26
:1108
e
17.
142. Anderson NL, Jackson A, Smith D, et al. SISCAPA
peptide enrichment on magnetic beads using an in-line
bead trap device.
Mol Cell Proteomics
2009;
55
cation by multiple reaction monitoring
mass spectrometry.
Clin Chem
2010;
:995
e
1005.
:291
e
305.
8
56
Search WWH ::
Custom Search